Hualan Biologicals: Wholly-owned subsidiary plans to establish a joint venture to explore the application scenarios of artificial intelligence technology in pharmaceutical research and development and drug safety management

2026-02-14 00:00:04

Hualan Bio announced that its wholly-owned subsidiary, Hainan Lingqing Digital Intelligent Medical Technology Co., Ltd., plans to jointly establish a joint venture with the technical team led by former CTO of Insilicom LLC in the United States, Yu Kaixian, and LIU JUN, an academician of the Chinese Academy of Sciences. Lingqing Digital Intelligent will invest 6 million yuan, holding 60% of the shares. The joint venture will focus on services related to drug repurposing and pharmacovigilance centered around knowledge graphs, aiming to explore applications of artificial intelligence technology in pharmaceutical R&D and drug safety management.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.